Healthcare Cost and Resource Utilization Related to Metastatic Renal Cell Carcinoma Treatment With Intravenous and Oral Agents

Study Overview
=================
Brief Summary
-----------------
A retrospective study to evaluate healthcare cost and resource utilization for patients with metastatic renal cell carcinoma who have been treated with IV or oral agents

Official Title
-----------------
A Healthcare Cost and Resource Utilization Analysis of Intravenous and Oral Agents in the Treatment of Metastatic Renal Cell Carcinoma

Conditions
-----------------
Renal Cell Carcinoma

Intervention / Treatment
-----------------
* Other: Non-Interventional


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis with metastatic renal cell carcinoma Prescription/administration of one of the IV or oral agents examined in the study Exclusion Criteria: Patients with other primary cancer diagnosis before RCC diagnosis Patients with pregnancy or HIV/AIDS
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients treated with IV agents<br>Metastatic renal cell carcinoma patients treated with IV agents | Other: Non-Interventional<br>* Other<br>|
| Patients treated with oral agents<br>Metastatic renal cell carcinoma patients treated with oral agents | Other: Non-Interventional<br>* Other<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distribution of Healthcare costs for patients treated with oral drugs used in the first-line treatment of Metastatic renal cell carcinoma (mRCC) | All-cause healthcare costs will be calculated in the first-line oral cohort as per-patient-per-month (PPPM) costs. | Up to 63 months | 
| Composite of Resource Utilization for patients treated with oral drugs used in the first-line treatment of mRCC | Total numbers and rates of inpatient, outpatient, and emergency room visits per patient will be calculated. | Up to 63 months | 
| Distribution of Healthcare costs for patients treated with IV drugs used in the first-line treatment of mRCC | All-cause healthcare costs will be calculated in the first-line IV cohort as per-patient-per-month (PPPM) costs. | Up to 63 months | 
| Composite of Resource Utilization for patients treated with IV drugs used in the first-line treatment of mRCC | Total numbers and rates of inpatient, outpatient, and emergency room visits per patient will be calculated. | Up to 63 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Medication Possession Ratio (MPR) for patients treated with oral drugs used in the first-line treatment of mRCC | MPR will be calculated for each index drug as the ratio of the sum of the total number of days' supply to the total number of days in the follow-up period. | Up to 63 months | 
| Medication Possession Ratio (MPR) for patients treated with IV drugs used in the first-line treatment of mRCC | MPR will be calculated for each index drug as the ratio of the sum of the total number of days' supply to the total number of days in the follow-up period. | Up to 63 months |